Our study provides insights into the molecular mechanisms of SWI/SNF loss in promoting drug resistance and suggests a potential therapeutic strategy to enhance chemotherapy response in patients affected by SMARCA4/2-deficient cancers. This evidence concerns the gene SMARCA4 and cancer.